EPISODE · May 9, 2026 · 1 MIN
Pfizer's Dividend Yield: A Bold Hunter's Path
from The Daily News Now! Business
Pfizers stock has plummeted, but its pharma prowess and potential pipeline payoffs make it a compelling buy. Despite bearish analyst views, the companys track record, recent acquisitions, and new treatments in migraine and oncology offer hope. A steady dividend and a 6.5% yield make it an attractive option for income-seeking investors. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2c1dfc35a5a6919c
NOW PLAYING
Pfizer's Dividend Yield: A Bold Hunter's Path
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m